Canada markets closed

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.2300+0.2500 (+12.63%)
At close: 03:59PM EDT
Full screen
Previous Close1.9800
Open2.0000
Bid2.2100 x 0
Ask2.2300 x 0
Day's Range2.0000 - 2.2400
52 Week Range1.2200 - 5.8400
Volume55,925
Avg. Volume43,772
Market Cap102.535M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateApr 10, 2024 - Apr 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.46
  • Baystreet

    Stocks in play: Theratechnologies Inc.

    Today announced two posters will be presented at the American Association for Cancer Research (AACR) ...

  • GlobeNewswire

    Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

    Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the cGAS/STING pathway potentiate and anti-PD-L1 immunotherapy tumor cell killing MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative

  • GlobeNewswire

    Theratechnologies Announces Update on its Preclinical Oncology Research Program

    Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities. The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendus